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Abstract
Hepatocellular carcinoma (HCC), the fifth most common 
cancer that predominantly occurs in liver cirrhosis 
patients, requires staging systems to design treatments. 
The barcelona clinic liver cancer staging system 
(BCLC) is the most commonly used HCC management 
guideline. For BCLC stage B (intermediate HCC), 
transarterial chemoembolization (TACE) is the standard 
treatment. Many studies support the use of TACE in 
early and advanced HCC patients. For BCLC stage 0 (very 
early HCC), TACE could be an alternative for patients 
unsuitable for radiofrequency ablation (RFA) or hepatic 
resection. In patients with BCLC stage A, TACE plus 
RFA provides better local tumor control than RFA alone. 
TACE can serve as bridge therapy for patients awaiting 
liver transplantation. For patients with BCLC B, TACE 
provides survival benefits compared with supportive 
care options. However, because of the substantial 
heterogeneity in the patient population with this stage, 
a better patient stratification system is needed to select 
the best candidates for TACE. Sorafenib represents the 
first line treatment in patients with BCLC C stage HCC. 
Sorafenib plus TACE has shown a demonstrable effect 
in delaying tumor progression. Additionally, TACE plus 
radiotherapy has yielded better survival in patients with 
HCC and portal venous thrombosis. Considering these 
observations together, TACE clearly has a critical role in 
the treatment of HCC as a stand-alone or combination 
therapy in each stage of HCC. Diverse treatment 
modalities should be used for patients with HCC and a 
better patient stratification system should be developed 
to select the best candidates for TACE.
Key words: Hepatocellular carcinoma; Transarterial 
chemoembolization; Sorafenib; Radiofrequency 
ablation; Hepatic resection; Liver transplantation
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This article describes the role of transarterial 
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chemoembolization (TACE) in the treatment of 
hepatocellular carcinoma (HCC) according to the 
barcelona clinic liver cancer (BCLC) staging system. 
Notably, TACE is the treatment of choice in the 
treatment of intermediate HCC (BCLC stage B). 
However, in clinical practice, TACE has been used as 
an alternative or combination therapy in patients with 
early or advanced HCC. Therefore, diverse treatment 
modalities, including TACE, should be considered for 
the best interests of patients with HCC.
Han K, Kim JH. Transarterial  chemoembolization in 
hepatocellular carcinoma treatment: Barcelona clinic liver 
cancer staging system. World J Gastroenterol 2015; 21(36): 
10327-10335  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v21/i36/10327.htm  DOI: http://dx.doi.
org/10.3748/wjg.v21.i36.10327
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most 
common type of cancer worldwide, predominantly 
occurs in patients with liver cirrhosis, and its rate of 
incidence is increasing[1,2]. HCC is a unique type of 
tumor because in addition to the extent of the tumor, 
the underlying liver function affects the prognosis[3]. 
The barcelona clinic liver cancer (BCLC) staging system 
staging system is the most widely accepted model 
worldwide as it integrates both tumor characteristics 
and general health status with hepatic function to 
provide a clinical algorithm to help guide treatment 
decision-making according to disease stages[4-6]. 
Notably, the BCLC staging system stipulates that 
transarterial chemoembolization (TACE) is the standard 
of care for patients with intermediate HCC. A growing 
body of evidence supports the use of TACE for patients 
with early and advanced HCC. This narrative review 
offers a critical appraisal of the available data regarding 
the role of TACE in the treatment of HCC based on the 
BCLC staging system.
BCLC STAGING SYSTEM
Recently, diverse HCC staging systems have been 
proposed, including TNM staging, the Cancer of the 
Liver Italian Program (CLIP), the Chinese University 
Prognostic Index (CUPI), the Japanese Integrated 
Staging (JIS) system, and the BCLC staging and 
treatment strategy[7-10]. Among these systems, 
only BCLC staging has been externally validated 
and allocates management choices to the following 
five different disease categories: very early, early, 
intermediate, advanced, and terminal. Importantly, 
liver expert groups (EASL and AASLD) generally 
agree that the BCLC system is preferred for HCC 
staging because it helps to predict survival outcomes 
and plan treatment options, and it is likely to be 
updated to reflect the latest molecular research to 
enhance prognostic and stage-specific management 
strategies[11,12]. We summarize the BCLC staging 
system and treatment strategies for each disease 
stage in Figure 1.
BCLC STAGING SYSTEM AND TACE
According to the BCLC system, TACE is the standard 
of care for both intermediate HCC. As described in 
the BCLC guidelines, this stratum of patients shows 
a survival benefit from TACE, which will be discussed 
later. However, in clinical practice, TACE has been 
widely used for different stages of HCC that extend 
beyond those recommended in the BCLC system 
(early or even advanced HCC). Irrespective of the 
heterogeneity in TACE techniques, chemotherapeutic 
agents, and treatment intervals, the term “conventional 
TACE” generally refers to the use of Lipiodol as an 
embolic material. For conventional TACE, various 
anticancer drugs are vigorously mixed with Lipiodol, 
which functions as a microvessel embolic agent, a 
chemotherapeutic agent carrier, and an augmenter of 
antitumor effects by promoting efflux into the portal 
vein[13]. As an alternative to conventional Lipiodol-
based regimens, non-resorbable microspheres loaded 
with cytotoxic drugs can be administered intra-
arterially to HCC patients. These particles are termed 
“drug-eluting beads” and were developed to sequester 
doxorubicin from solution and release it in a sustained 
manner. It has been reported that the amount 
of chemotherapeutic agents that reach systemic 
circulation compared with Lipiodol-based TACE can be 
substantially reduced, thus sharply increasing the local 
drug concentration[14].
The phase Ⅱ PRECISION V trial compared 
doxorubicin-loaded DEBs with conventional TACE and 
demonstrated a significant reduction in liver toxicity 
and drug-related adverse events. However, to date, 
no prospective study has yet reported a significant 
difference in clinical efficacy between Lipiodol-based 
TACE and DEB TACE[15].
Herein, we review the clinical implications of 
conventional TACE in each BCLC category.
VERY EARLY STAGE HCC OR STAGE 0 
(PST 0, CHILD-PUGH A)
This stage refers to patients with a single tumor ≤ 2 
cm or in situ. The American Association for the Study 
of Liver Diseases (AASLD) and European Association 
for the Study of the Liver (EASL) recommend that 
hepatic resection (HR) or liver transplantation (LT) 
should be the first option in BCLC 0 patients[11,12]. 
However, various risks, such as insufficient liver 
function, major blood loss, further injury to the normal 
parenchyma, and a shortage of liver donors, can 
prevent some patients from undergoing HR or LT[16,17]. 
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In stage 0 patients who are not suitable for HR or LT, 
diverse logoregional ablation techniques have been 
employed. Among these patients, radiofrequency 
ablation (RFA) is recognized to be the modality of 
choice. Recently, RFA was shown to be as effective 
as HR for small HCCs in terms of overall survival, 
and some investigators suggest that RFA may be 
the first option for patients with a single HCC that is 
2 cm or smaller, even when they can be surgically 
resected[18-20]. However, in patients with HCCs with 
a subcapsular or dome location or HCCs adjacent to 
the main bile duct or bowel loop, RFA may not be 
technically feasible because of the associated risks that 
include bowel perforation, major bleeding, and bile 
leakage[21].
Notably, TACE was previously only considered in 
this group of patients when HR, RFA, and LT were all 
not possible for various reasons. Kim et al[22] recently 
compared the effectiveness of TACE and RFA for 
stage 0 HCC, and reported no statistically significant 
difference in overall survival between the two groups, 
although RFA showed a better tumor response and 
delayed tumor progression. TACE may be considered 
a viable alternative treatment to RFA for treating 
single HCCs that are 2 cm or smaller when RFA is not 
feasible.
EARLY STAGE HCC OR STAGE A (≤ 3 
NODULES, ≤ 3 CM EACH, PS 0)
This stage includes patients with a single HCC or up 
to three nodules < 3 cm. Currently, if patients have 
well-preserved liver function without major vascular or 
lymphatic invasion, HR is considered to be the standard 
of care for early HCCs[12]. Unfortunately, in this stage, 
many patients do not satisfy the BCLC criteria for 
HR because HCC usually occurs in liver cirrhosis. As 
mentioned above, RFA has been found to be equally 
safe and effective as a first-line treatment for a single 
HCC up to 5 cm in diameter[23]. However, the local 
tumor progression rate, an important prognostic factor 
for RFA-treated HCC, was reported to sharply increase 
for tumors that exceeded 3 cm in size[24,25]. Notably, 
it is rarely possible to achieve complete ablation for 
tumors larger than 5 cm because of limitations for 
the ablation zone[26,27]. Kim et al[28] compared the 
effectiveness and safety of combined RFA and TACE to 
RFA alone in the treatment of mid-sized HCC (3-5 cm). 
In the combined therapy group, the long-term local 
tumor progression rates were lower than those of the 
RFA alone group (1-, 3-, 5-, and 7-year LTP rate: 9%, 
40%, 55%, and 66% vs 45%, 76%, 86%, and 89%, 
respectively; all p < 0.001). The observed advantages 
appear to be attributed to reduced heat-sink effects 
by occluding the arterial flow and allowing for more 
microscopic satellite tumor control[29-31].
Because the BCLC staging system categorizes 
solitary HCC as an early stage disease irrespective 
of tumor size, large single HCCs (> 5 cm) without 
vascular invasion also belong to the BCLC A stage. Jin 
et al[32] compared the outcomes of HR and TACE for 
solitary large HCC. They reported that HR offered a 
significantly better 5-year survival rate in the surgical 
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Figure 1  Updated barcelona clinic liver cancer staging system and treatment strategy.
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TACE showed a significant improvement in 2-year 
survival compared with best supportive care (OR = 
0.53; 95%CI: 0.32-0.89; p = 0.017)[41]. However, 
patients enrolled in these studies were not categorized 
according to the BCLC staging system and many 
patients with early HCCs were included. Furthermore, 
many patients had compensated liver function (Child-
Pugh A) and, thus, the role of TACE in HCC patients 
with Child-Pugh class B is relatively insufficient. 
Similarly, one of the great problems of BCLC stage B is 
the enormous heterogeneity of the population in tumor 
load, age, liver function, and potential comorbidities. 
However, no subgroup stratification exists for this 
stage, making it difficult to provide optimal treatment 
strategies[42]. Therefore, in clinical practice, TACE is 
often used outside of the current treatment guidelines.
Recently, several groups have proposed patient 
stratification systems. Bolondi et al[43] proposed a 
subclassification system of intermediate HCC based 
on key parameters related to tumor burden and liver 
function. The key parameters in such four-subgroup 
systems included the Child-Pugh score, tumor load 
(within or beyond the up-to-seven criteria), the 
ECOG performance and portal venous thrombosis, 
and the first and alternative treatment options were 
assigned to each category (Table 1). Ha et al[44] 
evaluated the usefulness of such subclassifications. 
In their study, patients belonging to the B1 and B2 
subclasses had a median overall survival of 41 or 
22 months, respectively. They did not observe any 
survival difference between the B3 and B4 groups (14.1 
mo vs 17.2 mo, p = 0.48) and proposed a modified 
subclassification system by merging the B3 and B4 
patients to facilitate per-subclass-based treatment 
options (median OS: 16.6 mo).
COMBINATION STRATEGIES
TACE + RFA
Despite the established survival benefit of TACE in 
patients with intermediate HCC, and as TACE is a 
palliative treatment that does not result in complete 
tumor necrosis, tumor recurrence after TACE is 
common. Additionally, repeat TACE might damage 
liver function and adversely affect patient survival. 
Nevertheless, RFA is known to provide better local 
control of disease than TACE and can achieve complete 
necrosis for small HCCs. However, the effectiveness 
of RFA in patients with intermediate or large HCC 
is unsatisfactory, with a relatively low complete 
necrosis rate that ranges from 29% to 70%, even if 
an overlapping technique or repeated procedures are 
used. However, Tanaka et al[45] investigated the long-
term effects of combination therapy for intermediate 
HCC. A total of 58 patients with BCLC stage B (single 
nodule > 5 cm or measuring more than 30 mm in 
diameter or two to three nodules, each measuring 
more than 30 mm in diameter, or more than three 
nodules, no vascular invasion, and no extrahepatic 
group than in the TACE group (65% vs 17%, p < 
0.01) irrespective of tumor size. In the study of Zhu 
et al[33], the propensity score matched findings also 
demonstrated a better 5-year survival rate in the 
surgical group than in the TACE group with propensity 
score matching (41.3% vs 18.5%, p = 0.007). 
Recently, Lee et al[34] conducted the largest study (159 
total patients: 91 patients for HR and 68 patients for 
TACE) to date that compared long-term survival after 
HR and TACE as the initial treatment for large solitary 
HCC (> 5 cm), which yielded contradicting results. 
The 5-year overall survival rates of HR and TACE were 
66% and 50%, respectively, and TTP was longer in the 
HR group. After propensity score matching (58 pairs), 
the overall survival of TACE patients was comparable 
to that of HR patients, and TTP remained significantly 
longer in patients treated with HR. The difference in 
overall survival between the two groups might result 
from differences in baseline patient characteristics 
rather than the treatment modality. They concluded 
that TACE could be considered as an alternative initial 
treatment for large solitary HCCs if HR is not feasible, 
particularly in patients with clinically presumed portal 
hypertension. A large, randomized, controlled study is 
warranted to compare the long-term outcomes of HR 
and TACE in the treatment of large solitary HCCs.
The Milan criteria (one lesion ≤ 5 cm in diameter 
or up to 3 lesions ≤ 3 cm) can be applied as a 
basis for selecting patients with cirrhosis and HCC 
for LT. However, liver transplant candidates greatly 
outnumber liver donors. It has been suggested that 
TACE can be used to downstage a tumor within the 
Milan criteria before transplantation[35-39]. Additionally, 
TACE can be used as a bridge to LT in cirrhotic patients 
with HCC within the Milan criteria[40].
STAGE B (INTERMEDIATE HCC)
The intermediate stage constitutes asymptomatic, 
large, or multifocal HCCs without evidence of vascular 
invasion or extrahepatic metastasis. TACE is the 
recommended treatment modality for this stratum of 
patients[4]. This recommendation is based on a meta-
analysis of seven trials, which demonstrated that 
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Table 1  Subclassification system for intermediate hepa­
tocellular carcinoma proposed by Bolondi et al [43]
BCLC substage B1 B2 B3 B4
Child-Pugh Score 5-6-7 5-6 7 8-9
Beyond Milan and 
Within Ut-7
In Out Out Any
ECOG-PS 0 0 0 0-1
PVT No No No No
1st option TACE TACE or TARE BSC
Alternative LT, 
TACE + 
ablation
SOR Research 
trials
TACE, SOR
LT
TACE: Transarterial chemoembolization; LT: Liver transplantation.
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metastasis) were included in that study. They reported 
that the 1-, 2-, 3- and 5-year overall survival rates of 
the combination therapy group (91%, 65%, 53%, and 
27%, respectively) were significantly better than those 
of the supportive care group (42%, 8%, 8%, and 
0%, respectively). The overall survival rates for the 
combination therapy group tended to be higher than 
those of patients treated with TACE alone in previous 
studies (1-, 2-, and 3-year survival rates of 75%, 
50%, and 29%, respectively). Although a large-scale 
randomized controlled trial will be required to compare 
those results with TACE alone, TACE combined with 
RFA seems to be a safe and effective treatment 
strategy for patients with intermediate HCC.
Systemic treatment with sorafenib
Sorafenib, an oral multikinase tyrosine inhibitor, is the 
treatment of choice in BCLC C patients. However, a 
subanalysis of the SHARP trial revealed that sorafenib 
was safe and effective, irrespective of whether 
patients were either BCLC stage B or C (median OS: 
14.5 mo in BCLC B stage vs 9.7 mo in BCLC C)[46]. 
Some investigators demonstrated that sorafenib may 
provide benefits for patients with BCLC B HCC who 
are ineligible for or have progressed after TACE[46,47]. 
Furthermore, it is suggested that patients who do not 
meet the allocated treatment criteria within a stage 
should be offered the next most suitable treatment 
within the same or next stage[11]. Patients with 
intermediate HCC who do not respond to TACE may 
benefit from sorafenib. Sorafenib will be discussed 
more thoroughly in the following section on the BCLC 
C stage.
STAGE C (ADVANCED HCC)
Emergence of sorafenib
This category applies to patients who have symptoms 
and/or vascular invasion or extrahepatic spread. 
No effective systemic chemotherapy exists for 
advanced HCC, and systemic chemotherapy might 
even adversely affect patient survival[46]. In this 
context, sorafenib, an oral multikinase inhibitor with 
antiproliferative and antiangiogenic effects, has 
emerged as a promising drug for advanced HCC 
interventions. The SHARP trial reported an improved 
median overall survival without significant drug 
toxicity in patients treated with sorafenib (10.7 mo in 
the sorafenib group vs 7.9 mo in the placebo group; 
HR = 0.69; 95%CI: 0.55-0.87; p < 0.001), and this 
improvement in survival was also identified in the 
Asian-Pacific population (6.5 mo in the sorafenib group 
vs 4.2 mo in the placebo group; HR = 0.68; 95%CI: 
0.50-0.93; p = 0.014)[48,49]. Subsequently, sorafenib 
has been considered as the standard of care for BCLC 
stage C HCC.
TACE and its combination with sorafenib
As demonstrated by the aforementioned previous 
studies, the survival benefit observed after sorafenib 
treatment is limited to less than 3 mo, which highlights 
the need for better treatment strategies. Under these 
circumstances, several investigators have reported 
that TACE has the potential to benefit this group of 
patients[50-55]. Chung et al[56] compared the efficacy 
and safety of TACE in patients with HCC who initially 
presented with main portal vein invasion. They showed 
that repeated TACE showed significant survival benefits 
compared with supportive care in both Child-Pugh 
class A (median OS: 7.4 mo vs 2.6 mo) and B (median 
OS: 2.8 mo vs 1.9 mo). Furthermore, irrespective 
of the use of sorafenib, the use of TACE to control 
intrahepatic HCC has been found to offer survival 
benefits compared with conservative management in 
patients with HCC and extrahepatic spread[57].
TACE-induced hypoxia in surviving tumor cells 
results in the release of angiogenic growth factors, 
which contribute to tumor recurrence or metastases 
and a worse outcome[58,59]. Sorafenib inhibits tumor 
cell proliferation by blocking the Raf-MEK-ERK signaling 
pathway at the Raf kinase level, and exerts an anti-
angiogenic effect by blocking vascular endothelial 
growth factor receptor-2 and -3 and platelet-derived 
growth factor receptor tyrosine kinase[60]. Therefore, 
in theory a combination of TACE with sorafenib might 
provide a benefit for patients with HCC. Choi et al[61] 
studied the time to progression and overall survival in 
patients with advanced HCC who were treated with 
sorafenib plus TACE versus sorafenib alone. They 
reported that the median TTP and OS in the combined 
group were longer than those in the monotherapy 
group (TTP: 2.5 mo vs 2.1 mo, p = 0.008; OS: 8.9 mo 
vs 5.9 mo, p = 0.009). Therefore, the addition of TACE 
to established sorafenib therapy has a demonstrable 
effect in delaying tumor progression in patients 
with advanced HCC, although the survival benefit is 
uncertain.
TACE plus radiotherapy
TACE combined with radiotherapy has resulted in 
improved outcomes for patients with HCC and portal 
vein thrombosis[62-70]. The rationale for this combined 
treatment is that reducing PVT with RT can delay 
intravascular tumor growth and the deterioration of 
liver function by preserving adequate portal flow, as 
well as by facilitating subsequent treatment of the 
primary tumor[66,67]. Recently, Kim et al[71] compared 
the efficacy of TACE with or without RT vs sorafenib 
for advanced HCC with PVT. In this single center study, 
patients were divided into three different pairs (TACE 
vs TACE + RT, TACE vs sorafenib, and TACE + RT vs 
sorafenib). By propensity score matched analysis, 
the TACE + RT group had a longer median time to 
progression and overall survival than the TACE-alone 
[102 pairs; TTP 8.7 mo vs 3.6 mo (p < 0.01); OS, 
11.4 mo vs 7.4 mo (p = 0.023)] and sorafenib groups 
[30 pairs; TTP, 3.4 mo vs 1.8 mo (p < 0.01); OS, 5.9 
mo vs 4.4 mo (p = 0.03)]. Although these findings 
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need to be verified with future randomized controlled 
trials, concurrent treatment with TACE and RT could 
represent an alternative option to the current standard 
sorafenib therapy for the treatment of HCC with PVT.
CONCLUSION
The BCLC staging system has served as the backbone 
of HCC treatment strategies as it stratifies patients 
according to outcomes and allocates treatments. 
Notably, despite the substantial heterogeneity of the 
HCC patient population with BCLC stage B, TACE has 
played a key role in the treatment of intermediate 
HCC. Additionally, as discussed in this review, TACE 
has been used as an alternative or combination 
therapy in patients with early or advanced HCC (Table 
2). Therefore, diverse treatment modalities should be 
utilized for the best interest of patients with HCC. In 
future studies, we should also develop a better patient 
stratification system to select suitable candidates for 
TACE and identify the best alternative treatment for 
patients who are refractory to TACE.
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